Dermatology News

A 2-year-old girl with a history of maple syrup urine disease presented to the dermatology clinic with an ongoing diaper rash.

The gap between patient-reported outcomes and clinician-assessed endpoints in rheumatology is well documented. Patients generally care about pain, fatigue and the emotional toll immune-mediated diseases can take, while physicians are more likely to pay attention to interleukin activity or C-reactive protein levels.

Despite advancements in the treatments for rheumatic diseases, early mortality rates associated with idiopathic inflammatory myositis have not improved in recent years, according to data presented at the EULAR 2020 E-Congress.

The FDA today approved a topical foam for the treatment of inflammatory lesions of rosacea in adults, according to a company press release.

Skin protection is important for reducing the risk for cancers, as well as for anti-aging and cosmetic reasons, in people of all complexions. However, many people of color often underestimate the dangers of the sun.

Baseline use of biologics and JAK inhibitors among patients with immune-mediated inflammatory disease, such as rheumatoid arthritis, psoriatic arthritis, psoriasis and other related conditions, is not associated with worse COVID-19 outcomes, according to a case series presented in the New England Journal of Medicine.

As the world faces the COVID-19 pandemic, wearing a mask or facial covering has been touted as one way to combat the spread of the virus. Most public places, such as grocery stores and essential locations, have now mandated customers and visitors must cover their mouth and nose. Meanwhile, health care providers and those who work in health care facilities have to wear full personal protective equipment, including a mask, for the duration of their shift.

The prevalence of antinuclear antibodies, markers of the body’s immune responses against its own cells, has increased significantly in the United States over the past several decades, particularly among adolescents and adults aged 50 years and older, according to data published in Arthritis & Rheumatology.

Patients with both chronic inflammatory disease and inflammatory bowel disease demonstrated higher health use and costs, compared with those with just chronic inflammatory disease, according to data published in BMC Rheumatology.

The FDA approved Pfizer’s supplemental new drug application for Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis, or AD.